Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL)

Hormone and Metabolic Research

Volumn 44, Issue 5, 2012, Pages 411-414

  Zovato, S ^a   Kumanova, A ^a   Dematte S ^b   Sansovini, M ^c   Bodei, L ^d   Di Sarra, D ^b   Casagranda, E ^b   Severi, S ^c   Ambrosetti, A ^c   Schiavi, F ^a   Opocher, G ^a   Paganelli, G ^d  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

177Lu DOTATATE; hereditary; paraganglioma

Indexed keywords

CISPLATIN; GEMCITABINE; LUTETIUM 177; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SUNITINIB; TETRAXETAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PARAGANGLIOMA; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; STEREOTAXIC SURGERY; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MEDIASTINAL NEOPLASMS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PARAGANGLIOMA; RECEPTORS, PEPTIDE;

EID: 84858699732     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1311637     Document Type: Article

References (21)

1. Cascn A, Lpez-Jimnez E, Landa I, Leskelä S, Leandro-Garca L J, Maliszewska A, Letn R, de la Vega L, Garca-Barcina M J, Sanabria C, Alvarez-Escol C, Rodrguez-Antona C, Robledo M. Rationalization of genetic testing in patients with apparently sporadic pheochromocytoma/paraganglioma. Horm Metab Res: 2009; 41 672 675
2. Qin Y, Buddavarapu K, Dahia P L. Pheochromocytomas: from genetic diversity to new paradigms. Horm Metab Res: 2009; 41 664 671
3. Opocher G, Schiavi F. Genetics of pheochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metabol: 2010; 24 943 956
4. Neumann H P, Sullivan M, Winter A, Malinoc A, Hoffmann M M, Boedeker C C, Bertz H, Walz M K, Moeller L C, Schmid K W, Eng C. Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J Clin Endocrinol Metab: 2011; 96 E1279 E1282
5. Comino-Mndez I, Gracia-Aznrez F J, Schiavi F, Landa I, Leandro-Garca L J, Letn R, Honrado E, Ramos-Medina R, Caronia D, Pita G, Gmez-Grana A, de Cubas A A, Inglada-Prez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli P, Hernndez-Lavado R, Daz J A, Gmez-Morales M, Gonzlez-Neira A, Roncador G, Rodrguez-Antona C, Bentez J, Mannelli M, Opocher G, Robledo M, Cascn A. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet: 2011; 43 663 667
6. Zeitler D M, Glick J, Har-El G. Preoperative embolization in carotid body tumour surgery: is it required? Ann Otol Rhinol Laryngol: 2010; 119 279 283
7. Garibaldi E, Bresciani S, Panaia R, Demastro E, Malinverni G, Gabriele P. Hereditary paraganglioma syndrome associated with SDHD gene mutations: a patient with multicentric presentation treated with radiotherapy. Case report. Tumori: 2011; 97 214 220
8. Joshua A M, Ezzat S, Asa S L, Evans A, Broom R, Freeman M, Knox J J. Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheocromocytoma. J Clin Endocrinol Metab: 2009; 94 5 9
9. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana C M, Bartolomei M, Baio S M, Sansovini M, Paganelli G. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging: 2008; 35 1847 1856
10. Kwekkeboom D J, Mueller-Brand J, Paganelli G, Anthony L B, Pauwels S, Kvols L K, O'dorisio T M, Valkema R, Bodei L, Chinol M, Maecke H R, Krenning E P. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med: 2005; 46 62 66
11. Julka P K, Doval D C, Gupta S, Rath G K. Response assessment in solid tumours: a comparison of WHO, SWOG and RECIST guidelines. Br J Radiol: 2008; 81 444 449 (Pubitemid 351957754)
12. Eisenhauer E A, Therasse P, Bogaerts J, Schwartz L H, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplar R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer: 2009; 45 228 247
13. Bravo E L, Kalmadi S R, Gill I. Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. Horm Metab Res: 2009; 41 703 706
14. Santarpia L, Habra M A, Jimnez C. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. Horm Metab Res: 2009; 41 680 686
15. Chrisoulisou A, Kaltsas G, Ilias I, Grossman A B. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocrine Relat Cancer: 2007; 14 569 585 (Pubitemid 350074048)
16. Havekes B, Lai E W, Corssmit EP M, Romijn J A, HJLM Timmers, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Im: 2008; 52 419 429
17. Rufini V, Castaldi P, Treglia G, Perotti G, Gross M D, Al-Nahhas A, Rubello D. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed & Pharmacol: 2008; 62 139 146 (Pubitemid 351381932)
18. Duet M. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med: 2003; 44 1767 1774 (Pubitemid 39663308)
19. Forrer F, Riedweg I, Maecke H R, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Im: 2008; 52 334 340
20. Van Essen M, Krenning E, Kooij P, Bakker W H, Feelders R A, de Herder W W, Wolbers J G, Kwekkeboom D J. Effects of Therapy with [177Lu-DOTA0, TYR 3]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma. J Nucl Med: 2006; 47 1599 1606 (Pubitemid 47545024)
21. Cecchin D, Schiavi F, Fanti S, Favero M, Manara R, Fassina A, Briani C, Allegri V, Sansovini M, Bui F, Paganelli G, Opocher G. Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas. J Clin Oncol: 2011; 29 171 174